Clinical Trials Logo

Adalimumab clinical trials

View clinical trials related to Adalimumab.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05590416 Recruiting - Adalimumab Clinical Trials

A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease

Start date: June 1, 2021
Phase:
Study type: Observational

This project is designed to test the hypothesis that adalimumab is clinically useful for patients with acuta Vogt-Koyanagi-Harada disease

NCT ID: NCT05155592 Recruiting - Uveitis Clinical Trials

Reduction or Discontinuation of TNF-α Inhibitor in Non-infectious Uveitis Patients

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

TNF-α inhibitors, like Adalimumab, have good efficacy in non-infectious uveitis, but long-term use can increase the risk of drugs, and the patient's financial burden is large. The objective of this study was to explore the reduction or withdrawal of Adalimumab in uveitis patients with stable drug control, and to evaluate the efficacy and safety of drug reduction in uveitis patients, as well as the impact on their vision prognosis.

NCT ID: NCT05015335 Recruiting - Uveitis, Anterior Clinical Trials

The Efficacy and Safety of Adalimumab in Non-infectious Anterior Pediatric Uveitis With Peripheral Vascular Leakage

Start date: August 19, 2021
Phase: Phase 4
Study type: Interventional

Children with anterior uveitis are prone to suffer from chronic recurrent course of intraocular inflammation and adverse effects of glucocorticosteroids (GCs) /immunomodulatory treatment (IMT) agents. The performance of adalimumab has been shown to be fairly favorable in treating refractory non-infectious uveitis. This study aims to assess the efficacy and safety of adalimumab for inflammatory flare prevention in non-infectious anterior pediatric uveitis with peripheral vascular leakage compared with methotrexate. Children weighed ≥ 30kg and aged between 4-16 years old with active chronic non-infectious anterior uveitis with peripheral retinal vascular leakage on ultra wildfield fluorescence fundus angiography (UWFFA) will be included. They will be treated with a predesigned inflammatory control regimen to reach inflammatory quiescence in 1 month. After that they will be treated with either MTX or adalimumab and regularly followed up for at least 6 months. The primary endpoint is treatment failure defined as any inflammatory fare with anterior chamber cell count grading increased from 0 to 1. Secondary endpoints are best corrected visual acuity (BCVA), inflammation parameters (keratic precipitates, vitreous haze grades), extent of vascular leakage, frequency of topical steroid eyedrops, systemic immunosuppressive drug load, and adverse events.

NCT ID: NCT04300686 Recruiting - Treatment Clinical Trials

A Pilot Study in Severe Patients With Takayasu Arteritis.

Start date: March 1, 2020
Phase: Phase 4
Study type: Interventional

Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. We classify TAK patients into 3 levels, including mild, moderate, and severe. And the biological agents tocilizumab and adalimumab are randomly prescribed in severe patients, to find out the relatively better treatment strategy, facilitating better intervention strategy in severe TAK patients.